New Biomarker Predicts Cancer Prognosis

Cancer diagnoses do not always come with a predictable future; sometimes, the impending course of the disease is uncertain. However, this terrifying unknown may soon be a thing of the past. When Jason Sheltzer, PhD, a Cold Spring Harbor Laboratory Fellow from Massachusetts Institute of Technology, and software engineer Joan Smith pored over the genomic profiles of 17,879 patients with cancer in search of common identifiable factors, they discovered a specific type of biomarker that can determine...

HPV+ Without CIN: Still at Risk for Cervical Cancer

A cellular abnormality called cervical intraepithelial neoplasia (CIN) is a precursor for cervical cancer. However, scientists have now found that women who are positive for human papillomavirus (HPV) and negative for CIN are still at a very high risk for developing cervical cancer. In a study published in the journal Cancer , researchers identified 576 healthy women through the National Cervical Screening Registry who were screened between 2005 to 2007 and tested negative for CIN. During a foll...

Atezolizumab Approved for Metastatic Nonsquamous NSCLC

After granting Priority Review, the FDA has approved atezolizumab (Tecentriq®, Genentech, Inc.), a monoclonal antibody, to be used in combination with carboplatin/paclitaxel/bevacizumab (CPB) for patients with previously untreated metastatic nonsquamous, non-small cell lung cancer (NSCLC) without EGFR or ALK tumor mutations. The approval was based on the open-label, three-arm IMpower150 trial (NCT02366143), for which patients were randomized 1:1:1 to a regimen of atezolizumab plus CPB, a regimen...

Luminal A Breast Cancer: Worse Outcome for Younger Patients

In a new study, investigators discovered that younger women diagnosed with breast cancer have poorer prognoses compared with their older counterparts. This link is specific to patients with hormone-receptor positive luminal A breast cancer, the most common subtype. The study classified patients diagnosed with invasive breast cancer into three groups according to age: 40 and under, 41 to 60, and over 60. In the 40 and under age group, patients with hormone-receptor positive luminal A breast cance...

Therapeutic Target Identified in Chemo Brain

Chemotherapy is a life-saving treatment for many patients with cancer. However, it can also leave patients with lasting neurological deficits through a condition commonly known as "chemo brain." "It's wonderful that they're alive, but their quality of life is really suffering," commented Erin Gibson, PhD, a postdoctoral researcher at the Stanford University School of Medicine. "If we can do anything to improve that, there is a huge population that could benefit." In a study published in Cell , D...
© Copyright 2018 i3 Health. All rights reserved.